Emcure Pharmaceuticals Limited IPO
Emcure Pharmaceuticals Limited IPO
Emcure Pharmaceuticals Limited IPO is listed on BSE and NSE with an issue price of ₹960–₹1008 per share. The stock debuted at ₹1325.05, delivering a listing gain of 31.5%. The IPO had a lot size of 14 shares and a minimum investment of ₹14,112.
- IPO Dates
- Jul 3, 2024 – Jul 5, 2024
- Price band
- ₹960-1008 per equity share
- Minimum Investment
- ₹14,112
- Issue size
- ₹1952.03 Cr
- Lot size
- 14
- Allotment Date
- Jul 8, 2024
- Listing
- Jul 10, 2024
- Listing At
- BSE, NSE
IPO timeline
-
Jul 3, 2024
Open Date
Completed
-
Jul 5, 2024
Close Date
Completed
-
Jul 8, 2024
Allotment Date
Completed
-
Jul 10, 2024
Listing Date
Completed
Price Summary
- Last closing
- 1,630.60 (61.77%)
- 52 week high
- 1,688.00
- 52 week low
- 983.00
- Last update
Emcure Pharmaceuticals Limited IPO Essentials
Emcure Pharmaceuticals Limited IPO Details
Emcure Pharmaceuticals Limited IPO is priced at ₹960-1008 per share with a total issue size of ₹1952.03 crore. The IPO has a lot size of 14 shares and is listed on BSE and NSE.
- Issue price
- ₹960-1008 per equity share
- Lot size
- 14 shares
- Face value
- ₹10 Per Equity Share
- Total issue size
- 1,93,65,346 shares
(aggregating up to ₹1952.03 crore) - Fresh issue
- 79,36,507 shares
(aggregating up to ₹800 crore) - Offer for sale (OFS)
- 1,14,28,839 shares
(aggregating up to ₹1152.03 crore) - Listing at
- BSE, NSE
- List price
- 1325.05(NSE)
- Listing date
- Registrar
- Link Intime India Private Ltd
- Lead manager
-
Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited
Market Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 14 | ₹14,112 |
| Retail(max) | 14 | 196 | ₹1,97,568 |
Emcure Pharmaceuticals Limited IPO Reservation
Emcure Pharmaceuticals Limited IPO reservation details show category-wise allocation of shares. Out of the total 19,483,388 shares, approximately 19.78% are reserved for QIB, 14.83% for NII, 34.61% for retail investors, and 29.67% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 5,779,850 (29.67%) | |
| QIB Shares Offered | 3,853,234 (19.78%) | |
| NII (HNI) Shares Offered | 2,889,926 (14.83%) | |
| bHNI > ₹10L | 1,926,618 (9.89%) | 9,174 |
| sHNI < ₹10L | 963,309 (4.94%) | 4,587 |
| Retail Shares Offered | 6,743,160 (34.61%) | 481,654 |
| Total Shares Offered | 19,483,388 (100%) |
Emcure Pharmaceuticals Limited IPO Analytics
Emcure Pharmaceuticals Limited IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Emcure Pharmaceuticals Limited IPO Subscription Status
Emcure Pharmaceuticals Limited IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 3,853,234 |
2,889,926
1,926,618
963,309
|
6,743,160 | 13,703,538 |
|
Day 1
03-07-24 05:00 PM
|
0.07 x |
2.71x
2.54x
3.04x
|
1.39 x | 1.32 x |
|
Day 2
04-07-24 05:00 PM
|
1.00 x |
13.67x
14.15x
12.70x
|
3.43 x | 4.98 x |
|
Day 3
05-07-24 05:00 PM
|
195.83 x |
48.28x
53.79x
37.26x
|
7.17 x | 67.84 x |
|
Total No. of Applications
|
bHNI | sHNI | Retail |
|---|---|---|---|
| 28,45,226 (Approx) | —x | —x | 5.7x |
Emcure Pharmaceuticals Limited Valuations
Earnings
- EPS Pre IPO
- ₹29.17/-
- EPS Post IPO
- ₹27.95/-
- P/E Pre IPO
- 34.55
- P/E Post IPO
- 36.07
Returns
- ROE
- 16.90%
- ROCE
- 19.37%
- RoNW
- 16.87%
Fundamentals
- Debt / Equity
- 0.67
- Price / Book
- 6.18
Emcure Pharmaceuticals Limited Financials( In Crs.)
| 31-Mar-24 | 31-Mar-23 | 31-Mar-22 | |
|---|---|---|---|
| Assets | 7,806.16 | 6,672.53 | 6,063.47 |
| Revenue | 6,715.24 | 6,031.72 | 5,918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| Net Worth | 2,952.28 | 2,501.13 | 1,987.55 |
| Reserves & Surplus | 2,722.40 | 2,293.77 | 1,987.55 |
| Total Borrowing | 2,091.94 | 2,202.42 | 2,102.19 |
Emcure Pharmaceuticals Limited Company & Offer Insights
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas.
The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in our covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023.
In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company's total revenue, respectively. The company's Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.
As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities in India. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files.
Emcure Pharmaceuticals has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.
As of September 30, 2023, the company's marketing and distribution network in India was supported by over 5,000 field personnel who regularly interacted with healthcare providers. The distribution network included over 5,000 stockists, served by 37 carry-and-forward agents.
Emcure Pharmaceuticals Limited Promoter(s)
Satish Mehta, Sunil Mehta are the company's promoters of Emcure Pharmaceuticals Limited.
Emcure Pharmaceuticals Limited IPO Issue Objectives
- •
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company
- •
- General corporate purposes
Emcure Pharmaceuticals Limited IPO - Anchor Investors
Emcure Pharmaceuticals raises Rs 583 crore from anchor investors ahead of IPO.
Marquee global investors including Abu Dhabi Investment Authority, Goldman Sachs, and Morgan Stanley bought more than Rs 71 crore worth of shares of the company from the anchor book.
In addition, several mutual funds houses including SBI, HDFC, ICICI Prudential, Whiteoak Capital, Aditya Birla Sun Life Trustee, Axis, Kotak, Nippon Life India, Mirae, Franklin India, UTI, Canara Robeco and Motilal Oswal also participated in the anchor book.
Among others, HDFC Life Insurance Company, ICICI Prudential Life Insurance Company, SBI Life Insurance Company, Amundi Funds, Neuberger Berman Emerging Markets Equity Fund, The Prudential Assurance Company, Bajaj Allianz Life Insurance Company, and Max Life Insurance Company, too, invested in the pharma firm.
Emcure Pharmaceuticals Limited IPO - Peers Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Limited | 27.54 | 27.54 | 163.22 | N/A | 21.27 | N/A | Consolidated |
| Dr. Reddy's Laboratories Limited | 335.22 | 335.59 | 1693.75 | 17.93 | 19.74 | 3.54 | Consolidated |
| Cipla Ltd. | 51.05 | 51.01 | 330.78 | 30.1 | 15.43 | 4.64 | Consolidated |
| Alkem Laboratories Ltd | 150.19 | 150.19 | 862.46 | 33.86 | 17.41 | 5.9 | Consolidated |
| Torrent Pharmaceuticals Ltd. | 48.94 | 48.94 | 202.57 | 57.74 | 24.15 | 13.95 | Consolidated |
| Mankind Pharma Limited | 47.75 | 47.68 | 233.73 | 45.3 | 20.43 | 9.24 | Consolidated |
| Abbott India Ltd. | 565.28 | 565.28 | 1740.71 | 47.43 | 32.48 | 15.4 | Standalone |
| J. B. Chemicals & Pharmaceuticals Limited | 35.66 | 34.85 | 188.37 | 50.49 | 18.9 | 9.34 | Consolidated |
Notes:
- Basic and Diluted EPS for peers are sourced from the audited financial statements for the relevant year.
- The P/E Ratio has been computed based on the closing market price of equity shares on BSE Limited on June 21, 2024, divided by the Diluted EPS.
- For listed peers, RoNW is computed as profit attributable to company owners divided by Total Equity attributable to the owners of the Company as on March 31, 2024.
- Net Asset Value ("NAV") is computed as the closing net worth divided by the equity shares outstanding as on March 31, 2024.
Emcure Pharmaceuticals Limited IPO - Strengths and Risks
Emcure Pharmaceuticals Limited IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.
Strengths
Risks
Contact Information
Contact Details
Emcure Pharmaceuticals Limited
+91 20 3507 0033
Plot No. P-1 and P-2,, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune -411 057
Registrar Contact Details
Link Intime India Private Ltd
+91-22-4918 6270
Frequently Asked Questions
Click any question to reveal the answer
Emcure Pharmaceuticals Limited IPO is a book-built IPO worth ₹1952.03 crore. The price band is ₹960–₹1008 per share. The IPO opens on Jul 3, 2024 and closes on Jul 5, 2024. It will be listed on BSE and NSE. Link Intime India Private Ltd is the registrar.
The price band of Emcure Pharmaceuticals Limited IPO is ₹960 to ₹1008 per share.
The lot size of Emcure Pharmaceuticals Limited IPO is 14 shares.
The minimum investment for Emcure Pharmaceuticals Limited IPO is approximately ₹14,112 based on the upper price band.
Emcure Pharmaceuticals Limited IPO opens on Jul 3, 2024 and closes on Jul 5, 2024.
The allotment date of Emcure Pharmaceuticals Limited IPO is Jul 8, 2024.
Emcure Pharmaceuticals Limited IPO is expected to be listed on Jul 10, 2024 on BSE and NSE .
Emcure Pharmaceuticals Limited IPO listed on Jul 10, 2024. It was issued at ₹1325.05(NSE) and is currently around ₹1630.60 as on 27-Apr-2026 3:30 PM, which is approximately 61.8% versus issue price. The 52-week high is ₹1,688.00.
Based on listing and post-listing performance, Emcure Pharmaceuticals Limited IPO delivered around 61.8% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.
To buy Emcure Pharmaceuticals Limited IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.
Emcure Pharmaceuticals Limited IPO valuation snapshot: P/E 36.07, EPS ₹27.95/-, P/B 6.18, RoNW 16.87%, and market cap N/A.
To apply for Emcure Pharmaceuticals Limited IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Emcure Pharmaceuticals Limited IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Emcure Pharmaceuticals Limited IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Emcure Pharmaceuticals Limited IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Emcure Pharmaceuticals Limited IPO allotment status on IPO Ji for quick and easy access.